Notably, the pan-mutant BRAF inhibitor PF-07799933, which inhibits BRAF mutant monomers and dimers and has antitumor activity in treatment refractory patients43, also increased ARF6-GTP levels in human melanoma (Fig. 4a). The gene discussed is BRAF; the disease is melanoma.